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Abstract
Background: Human African trypanosomiasis progresses from an early (hemolymphatic) stage, through CNS invasion to the
late (meningoencephalitic) stage. In experimental infections disease progression is associated with neuroinflammatory
responses and neurological symptoms, but this concept requires evaluation in African trypanosomiasis patients, where
correct diagnosis of the disease stage is of critical therapeutic importance.
Methodology/Principal Findings: This was a retrospective study on a cohort of 115 T.b.rhodesiense HAT patients recruited
in Eastern Uganda. Paired plasma and CSF samples allowed the measurement of peripheral and CNS immunoglobulin and
of CSF cytokine synthesis. Cytokine and immunoglobulin expression were evaluated in relation to disease duration, stage
progression and neurological symptoms. Neurological symptoms were not related to stage progression (with the exception
of moderate coma). Increases in CNS immunoglobulin, IL-10 and TNF-a synthesis were associated with stage progression
and were mirrored by a reduction in TGF-b levels in the CSF. There were no significant associations between CNS
immunoglobulin and cytokine production and neurological signs of disease with the exception of moderate coma cases.
Within the study group we identified diagnostically early stage cases with no CSF pleocytosis but intrathecal
immunoglobulin synthesis and diagnostically late stage cases with marginal CSF pleocytosis and no detectable
trypanosomes in the CSF.
Conclusions: Our results demonstrate that there is not a direct linkage between stage progression, neurological signs of
infection and neuroinflammatory responses in rhodesiense HAT. Neurological signs are observed in both early and late
stages, and while intrathecal immunoglobulin synthesis is associated with neurological signs, these are also observed in
cases lacking a CNS inflammatory response. While there is an increase in inflammatory cytokine production with stage
progression, this is paralleled by increases in CSF IL-10. As stage diagnostics, the CSF immunoglobulins and cytokines
studied do not have sufficient sensitivity to be of clinical value.
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Introduction
Human African trypanosomiasis (HAT), also known as Sleeping
Sickness, is caused by the protozoan hemoflagellate Trypanosoma
brucei ssp. After inoculation of the parasite by the tsetse fly vector,
the disease progresses through two stages. In the hemolymphatic,
or early stage of disease, parasites proliferate in the blood and
lymphatic system. In the meningoencephalitic, or late stage,
parasites penetrate the blood brain barrier (BBB) and persist and
proliferate in the CNS, causing an encephalitic reaction that leads
to death if untreated or inadequately treated [1]. Two sub-species
of African trypanosome give rise to HAT. T.b.gambiense is endemic
to West and Central Africa, with a chronic course of infection in
which late stage may not commence for months or years after
infection, and for which there is recent evidence for asymptomatic
infection [2,3,4]. T.b.rhodesiense is endemic in East and Southern
Africa, is distinguished by the SRA (serum resistance associated
gene) and exhibits a more acute pattern of progression than
T.b.gambiense, although there is considerable diversity in progres-
sion rate that may be related to parasite virulence variation and
host immunogenetics [5].
Animal model studies of T.brucei infection demonstrate that
dysregulated inflammatory responses are a major contributor to
the pathophysiology of infection, both systemically [6] and in the
brain [7,8], where it was hypothesised that the development of
neuropathology is associated with an astrocytosis regulated by the
CNS inflammatory/counter-inflammatory cytokine balance [9].
In humans, direct measurements of immune cell activation in
the brain are not possible for obvious ethical reasons. While gross
inflammatory pathology analogous to that observed in rodent
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models has been described in post-mortem material [10], our limited
understanding of the pathophysiology of CNS infection in HAT
derives from the observation of neurological symptoms and
analysis of patients’ cerebrospinal fluid (CSF) [11,12,13]. A
spectrum of neurological symptoms is observed in HAT infection.
This includes sleep, sensory, motor and psychiatric disorders as
well as the characteristic sleep disturbances that have given this
disease its common name of Sleeping Sickness [1].
Staging is critical to therapeutic decision making as late stage
infections of T.b.rhodesiense are currently treated with arsenical
drugs that induce a severe and sometimes fatal reaction known as
the post-treatment reactive encephalopathy (PTRE) in about 10%
of treated patients, half of whom die as a result giving an overall
drug mortality of 5% [12]. Currently, disease staging primarily
relies on the detection of trypanosomes in the CSF and/or an
elevation in the CSF white blood cell (WBC) count. The most
widely applied diagnostic cut off for CSF WBC counts to indicate
a late stage infection (WHO criteria) is .5 cells/ml [14], although
in the case of T.b.gambiense infection there is some evidence that
this value is too low and that effective early stage treatment may
still be administered in patients with up to 20 WBC/ml in the CSF.
It has also been proposed that HAT cases with between 5 and 20
CSF WBC/ml fall into an intermediate stage category, regardless
of whether trypanosomes are detected in the CSF [11]. In addition
to CSF cell counts, other biochemical and immunological markers
have been investigated to improve the sensitivity and specificity of
diagnostic staging. In late stage HAT there is an increase in CSF
protein level that is largely accounted for by immunoglobulin (Ig)
expression. High levels of intrathecal IgM synthesis are typical and
have been shown to be a sensitive marker for intrathecal
inflammatory responses and therefore of stage diagnostic value
in T.b.gambiense infections [15]. A number of stage-specific
alterations in cytokine and chemokine response have also been
described in CSF from HAT patients [8,16,17,18], and IL10 has
been proposed as a potential diagnostic marker for infection and
cure owing to the speed with which levels return to normal after
treatment [19].
As part of a study of the clinical evolution of T.b.rhodesiense HAT
[20], we have analysed in detail the parasitological and clinical
progression of HAT in a cohort of patients recruited in Serere in
2003, in Eastern Uganda. Because the parasites circulating in this
epidemic were genetically homogeneous [21], and the host
population comprised a single ethnolinguistic group, this set of
cases offers an opportunity to describe the evolution of HAT
independent of variations in parasite virulence, and to use the
clinical data to explore the relationship of inflammatory responses
in the CNS to clinical disease. In particular, we tested the
hypothesis that disease progression and neurological dysfunction
would be associated with increasing inflammatory (agonist) and
decreasing anti-inflammatory (antagonist) responses. We also
evaluated the stage diagnostic potential of CSF immunoglobulin
and cytokine responses in T.b.rhodesiense infection.
Methods
Ethics statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. All patients recruited received
written and verbal information explaining the purpose of this study
and gave informed written consent. All protocols were approved
by ethics committees in Uganda (Ministry of Health) and UK
(Grampian Joint Ethics Committee). Ethical consent forms were
designed in English and also translated into local languages.
Consent was given as a signature or a thumb-print after verbal
explanation. For those under 16 consent was given by their legal
guardian, and for those whose clinical condition prohibited full
understanding of the recruitment process, consent was gained
from a spouse or other family member.
Patient study sites and recruitment
115 HAT patients were recruited at Serere Health Centre,
Serere District, Eastern Uganda, between August 2002 and July
2003. This cohort of cases was drawn from of a larger multi-centre
study, for which study sites, recruitment protocols, treatment
regimens, disease progression characteristics and clinical exami-
nation methods have been published elsewhere [20]. All patients
belonged to the Ateso (Eastern Nilosaharan) ethnolinguistic group.
Patients with intercurrent infections of malaria, filariasis or
schistosomiasis were excluded from the study.
Staging criteria
Staging was carried out in accordance with WHO criteria [14].
These define late stage by the presence of parasites in the lumbar
CSF and/or a CSF WBC.5/ml in parasitemic individuals. In this
cohort, parasite counts in the CSF were determined by Neubauer
hemocytometer, and the definitive presence or absence of parasites
in the CSF by double centrifugation [22].
CSF and plasma analysis
Plasma and lumbar CSF were collected from all patients as part
of routine diagnostic and stage determination procedures. Paired
plasma and CSF samples were frozen in liquid nitrogen within 1 h
of collection, and maintained in liquid nitrogen until required for
analysis.
Control plasma and CSF samples for cytokine analysis were
obtained from 17 HAT suspects at Serere Health Centre and 18
HAT suspects at the LIRI Health Centre, Tororo, Uganda
respectively who were all later diagnosed as non-infected. In some
assays, limitations on the volume of plasma and CSF available
meant that a subset of patient samples that was effectively
randomly selected was analysed. Cytokines IFN-c, IL-6 and IL-10
concentrations were measured in CSF using a solid phase analyte
capture sandwich ELISA (OptiEIA set, Becton Dickinson-
Pharmingen, Oxford, U.K.) as previously described in [23]. Free
TNF-a was measured using a receptor binding assay as described
previously (BioLISA, Bender Med Systems, Wien, Austria) [24].
Author Summary
Human African trypanosomiasis, caused by the parasites
Trypanosoma brucei rhodesiense and T.b.gambiense, is
clinically defined by two diagnostic stages, an early stage
where the parasites appear to be localised to the blood
and lymphatic systems, and a late stage where the
parasites are also localised in the central nervous system
(CNS) and cause a meningoencephalitis, which is fatal if
untreated. We studied the progression between these
stages of infection in T.b.rhodesiense infections in Uganda.
Progression from early to late stage was associated with an
increase in inflammatory responses in the CNS as
measured by analysis of the cerebrospinal fluid. However,
contrary to predictions based on experimental model
studies, neither disease stage progression nor CNS
inflammatory responses were directly associated with
development of neurological symptoms. Our results
suggest that biological basis of the boundary between
the two diagnostic stages in this infection may not be clear
cut, with implications for therapeutic decision making.
CNS Inflammatory Response in HAT
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Cytokine assays limits of detection were IFN-c:1.8 pg/ml; IL-
10:1.6 pg/ml; TGF-b:19.2 pg/ml; IL-6:8.3 pg/ml; TNF-
a:22 pg/ml. For descriptive and inferential statistical analysis,
results below the limit of detection were assumed to be (0.56 limit
of detection value). As rank statistical methods were used this
assumption did not bias significance tests. Total IgM, IgA, IgG
and albumin were determined by nephelometry (ProSpec, Dade-
Behring, Marburg, Germany) as described in [15].
Blood-CSF barrier and intrathecal humoral responses
Blood-CSF barrier function was evaluated using the albumin
quotient (QALB). The cut off for dysfunction was calculated using
the formula
4z
Age
15
  
|10{3
Intrathecal immunoglobulin synthesis (IgLOC) was evaluated using
the method of Reiber [25]. Briefly, this analytic approach is based
on a reference set of 4300 normal CSF samples, from which an
upper hyperbolic discrimination curve QLIM defines the upper
limit of the immunoglobulin quotient (Q(Ig)) in the absence of
intrathecal Ig synthesis. Intrathecal Ig synthesis results in a Q(Ig)
lying above QLIM. The level of intrathecal synthesis of each isotype
(IgLOC) is derived from the formula
IgLOC~ Q(Ig){QLIM (Ig)|Igserum½ 
The results of this analysis were presented in quotient diagrams
[26] using CSF Statistics Tool software (CoMed GmbH, Soest,
Germany).
Data analysis and statistics
None of the continuous variable parameters examined could be
transformed to normality. Therefore differences between groups
were tested using the Mann-Whitney U-test, or the Kruskal Wallis
test followed by Dunn’s post-hoc test. Bivariate correlations were
evaluated using Spearmann’s rank correlation coefficient (rs).
Diagnostic outcomes as dependent variables were tested on
cytokine concentrations using logistic regression, and diagnostic
power was assessed using receiver operating characteristic analysis.
Diagnostic panel candidates were selected using mixed stepwise
logistic regression and optimal diagnostic cut offs were determined
using the prediction profiler in JMP6.0 (SAS Institute, Cary, NC,
USA).
Results
Study population
The study population comprised 35 early stage and 80 late stage
patients. The age, gender and diagnostic stage of these individuals
are presented in Table 1. There were no significant associations
between either gender or age and infection stage. Of the 80 late
stage cases, 77 were confirmed by detection of trypanosomes in the
CSF after double centrifugation. The remaining 3 where
trypanosomes could not be detected exhibited WBC counts
between 6 and 20/ml. Progression to late stage in this focus was
rapid with a median reported duration of illness of 8 weeks for late
stage cases.
Parasitaemia and CSF cell counts
Bloodstream parasitemias were scored on thick blood films. Late
stage median parasitemia was lower than in early stage, but this
difference was not significant (Table 2). However, parasitemia was
significantly inversely correlated to reported duration of illness. In
contrast, both CSF trypanosome and WBC counts increased
significantly with increasing duration of illness (rs = 0.53 p,0.0001
and 0.42 p,0.0001 respectively). Also, as would be expected given
that CSF trypanosome and WBC are diagnostic criteria, both were
significantly higher in late stage cases compared to early stage cases.
Plasma and CSF protein and albumin
Total CSF protein was significantly higher in late stage cases
compared to early stage cases and also increased in relation to
duration of disease (Table 2). Plasma albumin concentration was
below the normal reference range for European populations [15]
in both early and late stage cases and decreased with disease
progression as measured by both disease stage and reported
duration of illness (Table 2). In contrast, CSF albumin concen-
tration was significantly higher in late stage cases compared to
early stage cases. Likewise, the albumin quotient was significantly
increased in late stage cases compared to early stage cases and also
correlated to reported duration of disease (Table 2). Using the age
related cut off for normal albumin quotient (QALB), blood brain
barrier (BBB) dysfunction was indicated in 6% of early stage cases
and 42% of late stage cases.
Plasma and intrathecal immunoglobulin responses
Plasma IgG and IgA levels (Table 2) did not differ significantly
between early and late stage cases and fell within the normal
European reference range [15]. However plasma IgM levels in
both early and late stage cases were increased above the reference
range and increased with disease progression as estimated by stage
of infection and duration of disease. In early stage CSF samples, all
Ig isotype concentrations were within the reference range.
However, in late stage CSF samples IgM, IgG and IgA
concentrations were significantly increased compared to both
early stage and normal reference range values, and also were
significantly correlated with duration of disease. Intrathecal
synthesis of immunglobulins was determined (mg/l) in relation
to the upper hyperbolic discrimination line (QLim) [26] in quotient
diagrams (Figure S1). Intrathecal Ig synthesis was detected in 12%
early and 74% late stage cases (Table 3). The proportion of
intrathecally synthesised immunoglobulin in relation to total CSF
concentration also varied according to isotype, reaching a median
of 44% in the case of IgM synthesis in late stage cases. Overall, of
those late stage cases (n = 54) where intrathecal IgM synthesis was
detected, intrathecal synthesis of a second isotype occurred in 61%
(IgA) and 35% (IgG) of cases respectively. Intrathecal synthesis of
all 3 isotypes was detected in 30% of these cases. There was also a
significant correlation of intrathecal immunoglobulin synthesis
with duration of illness, CSF trypanosome concentration and CSF
white cell concentration for all isotypes.
Table 1. Characteristics of study population.
Diagnostic stage Early Late
Population(n) 35 80
Male 16 32
Female 19 48
Age (median, range) 20 (2–68) 21 (3–85)
Reported duration of
infection, days (median, range)
25 (2–90) 57 (6–157)
doi:10.1371/journal.pntd.0001857.t001
CNS Inflammatory Response in HAT
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CSF cytokine levels
The CSF IL-10 (Figure 1a) concentration was significantly
increased over control in both early and late infection stages and
also increased with progression from early to late stage. The IL-10
concentration also showed a significant positive correlation with
disease duration (rs = 0.41 p,0.001). There was no significant
difference between early and late stage cases for IFN-c (Figure 1b).
TNF-a levels (Figure 1c) in all control and early stage CSF samples
were below the assay limit of detection, but were detectable at a
significant level in 5/21 late stage cases. TGF-b levels (Figure 1d)
were significantly higher in early stage samples compared to late
stage although there was no significant correlation with duration of
infection. The CSF IL-6 (Figure 1e) concentration was increased
above control levels in both early and late stage cases, there was also
significant correlation to duration of infection (rs = 0.46 p,0.01).
When the relationships between the expression of each of the CSF
cytokines were evaluated, significant positive relationships were
identified between TNF-a and IL-10 (rs = 0.42 p,0.01); IL-6 and IL-
10 (rs- = 0.38 p,0.05); IL-6 and IFN-c (rs = 0.37 p,0.05) and a
negative relationship between TGF-b and IL10 (rs =20.4 p,0.001).
IL-10 and TGF-b concentrations were significantly predictive of
diagnosis stage in univariate logistic regression (likelihood ratio test
p,0.0001 for both cytokines). Each log unit increase in CSF IL-10
and TGF-b concentrations were associated with odds ratios (OR
Table 2. Serum and CSF albumin and immunoglobulin concentrations by stage of infection.
Parameter Reference range Earlya Latea
Correlation with
duration of illnessb
Serum
IgG (g/L) 8.0–18.0 20.9 (16.6–25.3) 22.5 (18.9–27.5) 0.18
IgA (g/L) 0.9–45.0 1.9 (1.3–2.7) 2.1 (1.6–2.6) 0.09
IgM (g/L) 0.6–2.5 6.3 (2.0–14.9) 13.6 (9.0–23.3)*** 0.35***
Albumin (g/L) 35.0–55.0 24.9 (21.1–31.6) 22.0 (17.6–26.9)* 20.28**
CSF
IgG (mg/L) ,40.0 27.6 (21.4–38.1) 76.0 (45.1–154)*** 0.39**
IgA (mg/L) ,6.0 1.1 (0.7–1.6) 6.0 (2.3–13.4)*** 0.46**
IgM (mg/L) ,1.0 0.66 (0.29–2.7) 64.2 (22.6–178)*** 0.6***
Albumin (mg/L) ,350 72.0 (46.5–102) 102 (72.5–190)*** 0.1
Protein (mg/L) ,500 171 (133–238) 365 (230–644)*** 0.35***
White cells/ml ,5 3 (2–5) 34 (12–76)*** 0.43***
Parasitemiac 3.5 (2–16.7) 2 (0.5–4) 20.2*
CSF trypanosomes/ml 0.0 (0.0–0.0) 2.5 (1.5–6.0)*** 0.53***
QALB 2.7 (2.0–3.6) 5.0 (3.2–7.7)*** 0.27**
a: Data are median (interquartile range). Difference between early and late stage parameters tested for significance using Mann-Whitney U-test.
b: Spearmann rank correlation coefficient.
Significance levels indicated:
*: p,0.05.
**: p,0.01.
***: p,0.0001.
c: Parasitaemia – thick blood film parasites per 10 fields at6400 magnification.
doi:10.1371/journal.pntd.0001857.t002
Table 3. Intrathecal immunoglobulin synthesis by diagnosis stage and reported duration of infection.
IgG IgM IgA
Any Intrathecal
synthesis
Early Stage n=32
% Cases with intrathecal synthesisa 6 9 3 12
Local synthesis (IgLOC) mg/l Median (IQR) 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.0 (0.0–0.0)
Late Stage n=74
% Cases with Intrathecal synthesis 26 73*** 46 *** 73 ***
Local synthesis (IgLOC) mg/l Median (IQR) 0.0 (0.0–8.2) 44.5 (0.0–163.0) 0.0 (0.0–3.4)
Correlation of local synthesis (IgLOC) with disease duration (rs) 0.22 " 0.33 "" 0.51 """
a: intrathecal synthesis where Q(Ig).QLIM.
Significantly higher frequency in late stage cases compared to early stage cases * and *** p,0.05 and p,0.0001 respectively, fishers exact test.
Significant correlation of intrathecally synthesised Ig concentration with duration of illness. ", "" and """, p,0.05, p,0.01 and P,0.001 respectively, Spearman
correlation test.
doi:10.1371/journal.pntd.0001857.t003
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[95% CI]) for late stage diagnosis of 4.0 (2.5–7.4) and 0.04 (0.01–
0.0.17) respectively. To determine if either would be of utility as a
late stage diagnostic, receiver operating characteristic (ROC)
curves were analysed. For IL-10 the area under the ROC curve
(AUROCC) was 0.85 but in order to achieve 100% specificity a
cut off value of 275 pg/ml only offered 14% sensitivity. For TGF-
b, the AUROCC was 0.86, and similarly the cut off for 100%
specificity (50 pg/ml) only offered 5% sensitivity. An optimal
combined panel of CSF IL-10, TGF-b, and IgM concentration
was identified using stepwise logistic regression analysis and with
discriminatory cut off levels for late stage determined on the
patient data of IL-10.66.4 pg/ml; TGF-b,159.5 pg/ml and
CSF IgM.89.2 mg/l. This panel offered an AUROCC of 0.97,
with 70% sensitivity for 100% late stage specificity.
Stage progression and neurological signs
Neurological signs including altered gait, tremors, incontinence,
cranial nerve neuropathy (facial nerve palsies), somnolence and
reduced Glasgow coma score (GCS) were observed in both early
and late stage patients, indicating early onset of neurological
involvement, with only moderate coma (GCS,12) being unrep-
resented in any early stage cases (Table 4). Of the neurological
Figure 1. CSF cytokine concentrations in HAT. IL-10 (a), IFN-c (b), TNF-a (c), TGF-b (d) and IL-6 (e) concentrations in control, early and late stage
HAT patients. Boxes indicate median and interquartile range, and whiskers represent 10th and 90th percentiles. ***p,0.001; *p,0.05 Mann-Whitney U
test. BLD=below limit of detection. ND: Not analysed due to insufficient material.
doi:10.1371/journal.pntd.0001857.g001
CNS Inflammatory Response in HAT
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signs assessed, only somnolence was observed to show a significant
(p,0.01) increase in frequency in relation to duration of illness
(OR for each log unit increase in duration of illness = 2.1 (95%
CI= 1.3–3.8)).
CNS immune responses and neurological signs
The relationships of neurological signs to intrathecal immuno-
globulin and cytokine synthesis were examined. There were no
significant differences in either intrathecal immunoglobulin levels
(Igloc) or cytokine concentrations (IL-10, IFN-c, TNF-a, TGF-b or
IL-6) in relation to the presence or absence of gait ataxia, tremors,
urinary incontinence, although cases with facial nerve palsies
exhibited a slight increase in intrathecal IgA concentration
(median (IQR) 0.0 (0.0–4.6) mg/l versus 0.0 (0.0–0.8) mg/l
p,0.05). However, cases with moderate coma (GCS,13)
exhibited substantially and significantly higher levels of intrathecal
synthesis of all Ig isotypes as well as IL-10 and IL-6 (Table 5). This
effect was not observed in cases with mild coma (GCS 13–14).
HAT patients with CSF white cell counts between 5 and
20/ml
In T.b.gambiense infection, it has been proposed that CSF white
cell counts of 5–20/ml, regardless of whether trypanosomes are
detected in the CSF, should be regarded as an intermediate stage
[11] that may be treated with pentamidine. In the cohort of
T.b.rhodesiense patients described in this paper, only 3 individuals
fell into this category. These patients were treated successfully with
melarsoprol and followed up for two years. The characteristics of
these subjects are presented in Table 6. All presented with normal
GCS, gait, and an absence of somnolence. All exhibited normal
BBB function. Unlike the late stage cases classified with white cell
counts .20/ml that all were positive for CSF trypanosomes after
double centrifugation, all three of these possible ‘‘intermediate’’
stage cases were negative for CSF trypanosomes. However 1/3
exhibited incontinence and cranial neuropathy. Furthermore, 2/3
exhibited intense intrathecal IgM synthesis, and 1/3 intrathecal
IgA and IgG synthesis (Table 6 and Figure 1b closed triangles).
Discussion
Our understanding of pathogenesis in HAT is limited by the
logistic difficulties of clinical studies in endemic areas. Studies in
animal models suggest that the development of systemic and CNS
pathology follows a dysregulation of host-inflammatory responses,
and that host-immune response variation may control the severity
of pathology [27]. African trypanosome CNS infection model
studies indicate that the development of neuropathology results
from inflammatory responses in the brain and it has been
hypothesised that pathogenesis may be controlled or limited by
counter-inflammatory responses [8].
In this study we selected a cohort of T.b.rhodesiense HAT patients
from Eastern Uganda who were exposed to a genetically
homogeneous parasite population [21] and were drawn from a
homogeneous ethnolinguistic (Ateso) host population. This ap-
proach enables us to minimise any confounding effects of natural
parasite variability [5] on the parameters and also to a limited extent
the effects of host genetic diversity on disease progression assuming
the close relationship between language and genetic variation
observed in other nilo-saharan populations [28]. We analysed the
development of CNS humoral and cellular immune responses and
their relationship to disease progression and neurological signs of
HAT. Disease progression was assessed both in relation to
diagnostic staging and the reported duration of disease.
Development of disease in the study group reported here was
rapid, with a median disease period of 8 weeks for late stage
infection, consistent with results previously reported from a larger
cohort of patients from the Soroti focus [20]. Overall parasitemia
levels were highest in early stage cases and fell in relation to
duration of infection.
In the plasma, IgM concentration increased with both
progression from early to late stage and reported disease duration.
Table 4. Neurological signs in early and late stage HAT
patients.
Neurological Sign %Early %Late
n=35 n=80
Gait Ataxia 63 52
Tremors 60 69
Incontinence 20 15
Neuropathy 29 31
Somnolence 57 55
GCS,15 14 14
GCS,12 0 10*
*p,0.05 Mann-Whitney U test.
doi:10.1371/journal.pntd.0001857.t004
Table 5. Relationship of neurological impairment to intrathecal humoral response (IgLOC) and cytokine responses.
CSF immune response Glasgow Coma Score Categories
GCS=15 (normal) GCS 13–14 (mild coma) GCS,13 (moderate coma)
n=91 n=8 n=8
IgG mg/l 0.0 (0.0–0.0) 0.0 (0.0–0.0) 70.5 (0.0–250.6)**
IgA mg/l 0.0 (0.0–1.1) 0.0 (0.0–1.0) 9.5 (4.4–11.8)***
IgM mg/l 0.5 (0.0–65.0) 20.1 (0.0–209.2) 178.0 (86.5–413.8)**
IL-10 pg/ml 40.9 (12.6–104.3) 27.1 (7.3–86.1) 266.9 (94.4–351.8)**
IL-6 pg/ml 12.0 (6.8–17.5) 17.8 (9.1–41.5) 172.7 (78.8–257.7)**
Note: All data are median (IQR). Significant difference to response in normal GCS cases (Dunns post hoc test) indicated in bold and.
**p,0.01.
***p,0.001.
doi:10.1371/journal.pntd.0001857.t005
CNS Inflammatory Response in HAT
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No similar increases were evident for plasma IgA and plasma IgG,
which also remained within or close to the reference range
concentrations described for healthy European subjects. This
result is consistent with observations in both mouse and bovine
models of a predominant polyclonal B-cell activation in trypano-
somiasis [29]. Although IgM responses have been previously
described in T.b.gambiense HAT, there has only been one previous
report of elevated IgM in the serum and CSF of T.b.rhodesiense
HAT patients [30]. Plasma albumin levels fell with disease
progression. While this phenomenon may be expected as part of
a negative acute phase response in early infection [31], in more
chronic infection it is possibly also a consequence of liver
pathology, albuminuria resulting from kidney damage, and
cachexia [32].
In the CSF, total protein increased with stage progression and
reported disease duration, consistent with previous observations
for both T.b.gambiense and T.b.rhodesiense. The CSF protein level
has been recognised as a useful stage diagnostic tool in HAT [14]
but it is interesting to note that in this study of T.b.rhodesiense
patients, the median late stage CSF protein concentration is
lower than the recommended diagnostic cut off for staging
employed in T.b.gambiense cases (370 mg/l). The increase in CSF
protein is accounted for at least in part by the large and
significant increases in CSF IgM, IgG and IgA concentration.
Similar increases have been described previously for T.b.gambiense
infection [15]. The increase in CSF immunoglobulin level is a
product of both intrathecal immunoglobulin synthesis and
accumulation of serum-derived immunoglobulins in the CSF as
a result of a reduction in CSF flow and turnover rate [25,33].
This is evident in this study from the significant increase in QALB
levels with both stage progression and disease duration, and
indicates a reduction of either CSF production in the choroid
plexus or outflow of CSF into venous circulation. In order to
measure intrathecal synthesis of immunoglobulin we used the
hyperbolic discrimination curve QLIM as cut off for non-CNS
derived Ig [33]. Intrathecal Ig synthesis (IgLOC) was detected in
few (12%) early stage cases but commonly (70%) in late stage
cases. In contrast to the findings from similar studies in
T.b.gambiense infection [15], intrathecal Ig synthesis in T.b.rhode-
siense HAT was predominantly a single class (IgM) response and 2
or 3 class responses were considerably less common. Overall,
while intrathecal Ig synthesis in late stage infection provides clear
evidence of the activation of humoral immune responses by
trypanosomes in the CNS, it does not offer the sensitivity or
specificity required to be effective as a stage diagnostic. None of
the early stage cases in this study where intrathecal Ig synthesis
was detected relapsed (over a 1 year follow up period) after
suramin treatment, indicating that the diagnostic decision to
classify these cases as early stage was correct. In T.b.gambiense
infection a similar frequency of early stage cases exhibiting Ig
synthesis has been described [15].
CSF cytokine concentrations were measured as indicators of
cellular immune activation in the CNS. Increases in IL-10 and IL-
6 concentration with stage progression are consistent with previous
studies in both T.b.rhodesiense [19] and T.b.gambiense infection [16].
In this study we further observed an increase in TNF-a
concentration and a decrease in TGF-b concentration with
progression to late stage. The increases in CSF cytokine
concentrations were not restricted to late stage cases only. CSF
concentrations of IL-6 and IL-10 were also elevated over control
levels in early cases, and provide evidence of early activation of
CNS cellular responses and suggest, as has been shown in rodent
models [10], that there may be very early CNS involvement in
HAT at a stage when patients are diagnostically classified as early
stage and effectively treated with suramin. While further research
is required into this phenomenon, one possibility is raised by
observation that trypanosomes may readily penetrate the vascular
endothelial basement membrane in some regions of the brain
while still being unable to traverse the parenchymal basement
membrane [34]. Such a process would bring trypanosomes in
contact with astrocytes, and thus initiate neuroinflammatory
responses. An increase in TNF-a concentration was only observed
in late stage cases, and therefore is consistent with the mouse
model of CNS infection [8]. With respect to the reduction in CSF
TGF-b concentration with stage progression, while we were
unable to measure CSF TGF-b in a sympatric control population,
published data on CSF TGF-b levels in normal subjects (266 pg/
ml [35]) suggest that in both early and late stage of infection TGF-
b CSF concentrations are reduced below control levels. The
reciprocal relationship of TGF-b and TNF-a concentrations in the
CSF observed in disease progression is consistent with the
mutually antagonistic anti- and pro-inflammatory properties of
these two cytokines. TNF-a is a mediator of inflammatory
neuropathology and its expression has been observed in associa-
tion with astrocyte activation in mouse models of late stage HAT
[36] as well as having been associated with disease severity in HAT
[37]. TGF-b functions as a regulatory cytokine that can modulate
inflammatory reactions in the CNS [38], for example through
suppression of pro-inflammatory TNF-a expression in astrocytes
[39], and the host TGF-b response has been implicated in the mild
presentation of HAT observed in Malawi [23]. However, this does
not account for the increase of CSF IL-10 with disease
progression, as IL-10 is also an anti-inflammatory mediator [40].
The strong correlation between TNF-a and IL-10 levels in the
CSF indicates the activation of distinct cellular compartments in
the CNS during infection, and identification of the CNS cellular
sources of IL-10, TNF-a and TGF-b in HAT will require further
work in model systems, and to determine if distinct subsets of brain
macrophages are involved in inflammatory/counterinflammatory
regulation as has been observed in in vitro models of murine brain
macrophage activation [41]. We observed no difference in CSF
IFN-c concentration between early and late stage. This result is
Table 6. Details of potential ‘‘intermediate-stage’’ cases.
Case Sex Age GCS
CSF
WBC/ml
CSF
DCa
Normal
gait? Tremors? Incontinence? Neuropathy? Somnolence?
QALB
Normal?
IgG
IF%
IgA
IF%
IgM
IF%
Ser72 F 28 15 10 nil Y N N N N Y 0 0 85
Ser40 M 13 15 9 nil Y N Y Y N Y 0 0 0
Ser99 M 33 15 16 nil Y N N N N Y 35 35 90
a: CSF DC: Detection of trypanosomes after double centrifugation of the CSF.
doi:10.1371/journal.pntd.0001857.t006
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not consistent with the close relationship of brain IFN-c synthesis
with disease progression described in the mouse model of African
trypanosomiasis [8].
Cytokines in the CSF have previously been proposed as
potential stage diagnostic markers [16,19]. In this study, while
IL-10 and TGF-b were predictive of diagnostic stage, they were
insufficiently sensitive to be developed as effective staging markers,
either individually or in combination with CSF IgM concentra-
tion.
Through analysis of immunoglobulin and cytokine responses in
the CNS in relation to stage progression in T.b.rhodesiense HAT, it is
possible to test the hypothesis that neurological dysfunctions
observed in HAT are manifestations of inflammatory neuropa-
thology. Neurological signs (gait abnormalities, tremors, inconti-
nence, cranial nerve neuropathy, somnolence and mild coma)
were equally probable to be observed in both early and late stage
cases, and the only significant difference in incidence of
neurological symptoms was for moderate coma which was never
observed in early stage cases. This result is consistent with
observations in a larger multi-centre study in Uganda [20]. While
somnolence was equally probable in early and late stage cases, its
incidence did increase with increasing reported duration of
infection. We then analysed whether any relationship existed
between CNS humoral and cytokine responses and neurological
signs. Intrathecal Ig and CSF cytokine synthesis did not vary
according to the presentation of gait ataxias, tremors, inconti-
nence, facial nerve palsies, somnolence and mild coma. Therefore
these neurological symptoms of HAT may have a non-immuno-
logical basis. However, individuals presenting with moderate coma
presented elevated intrathecal IgG, IgA and IgM synthesis as well
as significantly increased CSF IL-10 and IL-6 concentrations. In
one respect this finding is to be expected, as of all the neurological
signs that were investigated, moderate coma was only observed in
diagnostic late stage cases. However, the moderate coma cases
showed no significant increase in CSF IFN-c, TNF-a or TGF-b in
relation to mild or no coma cases. This suggests that inflammatory
cytokine responses including TNF-a and IFN-c do not increase
with disease severity and this is not consistent with findings in
experimental models and other clinical studies [10].
Finally, we observed a small number (3) of cases of HAT with
CSF WBC concentration 6 and 20/ml. These cases were classified
as late stage cases, however it was noted that these were the only 3
cases in the study where trypanosomes were not detected in the
CSF even after double centrifugation. It is intriguing to speculate
that these cases might present the first indication that, as is the case
in T.b.gambiense infection, there may be an ‘‘intermediate’’ or
‘‘early-second stage’’ of infection [13,15] in T.b.rhodesiense HAT.
However such an interpretation would require the study of
considerably more cases of this type, and while all three cases
showed normal BBB function, 2 of the cases presented an intense
intrathecal IgM synthesis (Fig. 1b) despite neither of these
individuals showing any neurological signs.
In conclusion, in T.b.rhodesiense HAT, increasing levels of
intrathecal immunoglobulin synthesis and CNS pro-inflammatory
cytokine expression were associated with disease progression from
early to late stage, although these were of limited diagnostic value.
While intrathecal immunoglobulin synthesis was associated with
the development of coma, it was not associated with any of the
other typical neurological sequelae of HAT, which were also not
related to CSF inflammatory or counter-inflammatory cytokine
levels. Neuroinflammatory responses in correctly diagnosed early
stage cases and cases with a similarity to the intermediate stage of
T.b.gambiense HAT suggest there may be an early CNS involve-
ment prior to the detectable invasion of the brain by the parasite
and that effects on the CNS may be mediated indirectly by the
parasite while it is still localised in the haemolymphatic system.
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Figure S1 Quotient diagrams for CSF IgG, IgA and IgM
in HAT. (a) early stage and (b) late stage HAT patients. Values
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and 20 cells/ml.
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